Mark I NAAK

This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (September 2013) (Learn how and when to remove this template message)

The Mark I NAAK (left) and its training kit (right)

In the United States military, the Mark I NAAK, or MARK I Kit, ("Nerve Agent Antidote Kit") is a dual-chamber autoinjector: Two anti-nerve agent drugs—atropine sulfate and pralidoxime chloride—each in injectable form, constitute the kit. The kits are only effective against the nerve agents tabun (GA), sarin (GB), soman (GD) and VX.

Typically, U.S. servicemembers are issued three MARK I Kits when operating in circumstances where chemical weapons are considered a potential hazard. Along with the three kits are issued one CANA (Convulsive Antidote, Nerve Agent) for simultaneous use. (CANA is the drug diazepam or Valium, an anticonvulsant.) Both of these kits are intended for use in "buddy aid" or "self aid" administration of the drugs prior to decontamination and delivery of the patient to definitive medical care for the condition.

A newer model, the ATNAA (Antidote Treatment Nerve Agent Auto-Injector),^[1] has both the atropine and the pralidoxime in one syringe, allowing for simplified administration.

The use of a Mark 1 or ATNAA kit inhibits the nerve agents' purpose, thereby reducing the number of fatal casualties in the advent of chemical warfare. The kits should only be administered if nerve agents have been absorbed or inhaled.

References[]

• U.S. Army Medical Research Institute of Chemical Defense, Medical Management of Chemical Casualties Handbook, Third Edition (June 2000), Aberdeen Proving Ground, MD, pp 118-126.